McKesson Corporation’s (MCK) dedicated business focused on supporting the commercialization of cell and gene therapies, InspiroGene, has been selected by Vertex Pharmaceuticals Incorporated (VRTX) to expand commercial distribution options for CASGEVY. InspiroGene will partner with Vertex to expand distribution options for CASGEVY.CASGEVY (exagamglogene autotemcel), the first CRISPR-based gene-editing therapy approved by the FDA, is indicated for the treatment of patients 12 years and above with sickle cell ...